ArticleResearch in pharmaceutical sciences2026
Synergistic cytotoxicity of recombinant IGFBP-3 and cisplatin in HPV18-positive HeLa cells
Article in Research in pharmaceutical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- IGFBP3 and cisplatin synergistically suppress HeLa cell proliferation and migration through NRF2 inhibition.Research in pharmaceutical sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Insulin-like growth factor-binding protein-3 (IGFBP-3), a tumor suppressor and inhibitor of nuclear factor kappa B (NF-kB), has emerged as a promising candidate for therapeutic application across diverse pathological conditions. Given NF-kB's role in cervical cancer development and cisplatin resistance, this study examines the effects of recombinant human IGFBP-3 (rhIGFBP-3), alone and in combination with cisplatin, on NF-kB levels, inflammatory modulation, and apoptotic response in HeLa cells, and investigates whether rhIGFBP-3 can reduce the cisplatin dose. Experimental approach: The impact of rhIGFBP-3, alone and in combination with cisplatin, on HeLa cells' viability was evaluated by assessing cell viability (MTT assay); apoptosis (cell cycle analysis, TUNEL, annexin V/PI staining, Bax/Bcl-2 ratio, caspase activity); and NF-kB p65 levels (western blot). Gene expression of inflammatory cytokines and enzymes (IL-6, IL-8, COX-2, iNOS) was analyzed by RT-PCR. Findings/Results: Cisplatin and rhIGFBP-3 inhibited HeLa cell growth in a concentration-dependent manner (IC Conclusion and implications: Our study demonstrated that rhIGFBP-3 enhanced cisplatin efficacy by promoting apoptosis and attenuating inflammation, highlighting its potential as both a cisplatin adjuvant and a monotherapy in HeLa cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.